This is a working overview of tirzepatide, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-08-01. Anything still debated is marked as such rather than presented as settled.
Identity and purity are established with reversed-phase high-performance liquid chromatography, often paired with mass spectrometry for confirmation of the expected mass. Peptide mapping after enzymatic digestion verifies the primary sequence and detects substitutions. Size-exclusion chromatography quantifies aggregates and fragments, which are the impurities most often tracked for peptides of this size. Residual solvents, counterions, and water content fall under separate tests described in pharmacopeial chapters. Circular dichroism or nuclear magnetic resonance may be used in research settings to probe secondary structure, though such methods are less common in routine release testing.
Peptide active ingredients of this type are typically supplied as lyophilized powder because the dry form resists hydrolysis during transport. The material is hygroscopic, so vials are usually equilibrated to room temperature before opening to avoid condensation on the solid. Repeated freeze-thaw cycles can promote aggregation and are generally avoided by aliquoting stock into single-use portions. Personnel handling the powder work in controlled environments to limit inhalation of fine particles. Written procedures usually specify these steps rather than leaving them to individual judgment.
Long-term storage of the solid generally relies on temperatures at or below minus twenty degrees Celsius, while short-term working stocks may be held refrigerated. Light exposure is limited because photodegradation can alter side chains over extended periods. Solutions prepared for analysis are less stable than the dry powder and are typically used within the same working day. Buffer choice matters, since some aqueous conditions favor deamidation or oxidation at specific residues. Stability data are usually generated under defined accelerated conditions and then extrapolated with stated assumptions.
Structural work on the molecule centers on a C20 fatty diacid moiety attached through a linker to the peptide backbone. This side chain promotes reversible binding to serum albumin, which slows renal clearance and supports a prolonged action profile. The peptide backbone incorporates aminoisobutyric acid substitutions that limit recognition by digestive enzymes. Together these modifications produce a molecule that is stable enough for subcutaneous delivery but still dependent on careful manufacturing control. Analytical characterization of the active pharmaceutical ingredient typically follows the conventions used for other synthetic peptides.
Tirzepatide is a synthetic peptide composed of 39 amino acids. It acts as a dual agonist at two incretin receptors, the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. The molecule was designed by modifying the native sequence of glucose-dependent insulinotropic polypeptide to improve metabolic stability and extend its circulation time. Its structure includes several non-natural amino acid residues and a fatty acid side chain. These features distinguish it from earlier single-receptor incretin analogs studied in the same period.
The compound first appeared in the scientific literature as an investigational agent for type 2 diabetes. Clinical development proceeded through phase 1, phase 2, and phase 3 programs that measured glycemic control as a primary endpoint while recording body weight as a secondary outcome. Regulatory approval in the United States followed in 2022 for glycemic control, and a separate indication for chronic weight management was added later. Subsequent trials have examined cardiovascular outcomes in adults with elevated cardiovascular risk. Debates continue over how much of the observed effect derives from each receptor arm.
| Property | Value | Notes |
|---|---|---|
| Typical supplied form | Lyophilized powder | Hygroscopic, seal promptly after opening |
| Long-term storage temperature | At or below minus 20 C | Protect from repeated freeze-thaw |
| Working solution stability | Hours when refrigerated | Use within the same working day |
| Primary purity method | Reversed-phase HPLC | Often paired with mass spectrometry |
| Aggregate measurement | Size-exclusion chromatography | Reports high-molecular-weight species |
溶解操作一般使用注射用水或适宜的水性缓冲液，必要时加入少量助溶剂以改善溶解速度，但应避免剧烈涡旋振荡，因为剪切力可能促进聚集。配制后的溶液在冷藏条件下的稳定时间通常短于固体形态，具体时限取决于浓度、缓冲体系与容器材质。是否加入防腐成分，则取决于用途是否为多次取样。
定量分析的主流方法是反相高效液相色谱联用紫外或质谱检测，利用肽在疏水固定相上的保留行为确定纯度与含量。对于生物基质中的浓度测定，常采用液相色谱串联质谱，并配合固相萃取或蛋白沉淀进行样品前处理。免疫分析法也可使用，但可能受到结构相关肽的交叉反应干扰。
纯度评估通常综合反相色谱、体积排阻色谱与质谱三方面信息：前者反映疏水性杂质，后者反映聚集体，质谱则确认分子量与主要降解产物。有关降解途径的完整图谱——例如脱酰胺、氧化与水解各占多大比例——在不同储存条件下仍有差异，属于需要逐案验证的问题。
该化合物的名称与结构由国际非专利名称体系统一维持，不同文献中出现的同义写法主要在拼写顺序或盐形式描述上不同。研究者通常通过受体结合实验、细胞内环磷酸腺苷积累测定以及动物模型来确认其双激动活性。相当一部分分子层面的细节——例如两条受体通路之间的信号交叉作用——尚处于开放问题状态。
当前公开资料把 tirzepatide 归为肠促胰素类受体双重激动剂。它并非激素天然变体，而是经过序列改造的工程化肽。其分子量、等电点与疏水性等基础参数已在药典和化学数据库中收录，可作为分析检测和质量研究的参照。
Stability depends strongly on physical form. The dry powder is generally regarded as stable for extended periods when held at or below minus twenty degrees Celsius in a sealed, desiccated container. In solution, degradation pathways include deamidation of asparagine and glutamine residues, oxidation of methionine, and aggregation. Reaction rates for these pathways rise with temperature. Repeated freezing and thawing of solutions promotes aggregation, and light exposure can accelerate some oxidative changes. Buffer composition and pH influence which pathway dominates at a given temperature.
Regulatory and quality discussions place the peptide within established guidance for synthetic peptides and biologics. Forced degradation studies, in which samples are exposed to heat, acid, base, peroxide, and light, identify likely degradation products and validate the selectivity of analytical methods. Reference standards allow comparison across laboratories and production batches. Purity specifications reported in the literature usually combine chromatographic purity with mass confirmation. Which impurity thresholds are meaningful for long-term behavior is still debated, and no single universal specification has been adopted across all jurisdictions.
Published work supports the view that engaging two incretin receptors produces changes in glucose handling and body weight larger than those seen with single-receptor activation. Why that difference arises is not fully settled. Open questions include how much of the observed weight effect depends on central versus peripheral signaling, and whether the two receptors form interacting complexes. Most reported findings come from controlled trials and animal models, and translation between species is imperfect. Further research is expected to refine these points over time.
Tirzepatide is a synthetic peptide built from 39 amino acid residues. Its sequence is related to human glucose-dependent insulinotropic polypeptide, with modifications that include a C-terminal extension and a C20 fatty diacid joined through a linker. Those changes raise the molecule's affinity for serum albumin, which slows renal filtration and lengthens the time it stays in circulation. The free base has an average molecular mass near 4813.5 daltons. The compound is made by solid-phase peptide synthesis followed by chromatographic purification.
=== Magnesium deficiency === Injected magnesium sulfate is used as a replacement therapy for magnesium deficiency. Orally administered magnesium sulfate is laxative and thus the magnesium is not well absorbed
NF-kappa+B at the U.S. National Library of Medicine Medical Subject Headings (MeSH) Sankar Ghosh (2006). Handbook of Transcription Factor NF-κB. Boca Raton: CRC. ISBN 978-0-8493-2794-0. Thomas D Gilmore. "The Rel/NF-κB Signal Transduction Pathway". Boston University. Retrieved 2007-12-02.
The East Central Conference is a former high school athletic conference in Wisconsin. Originally founded in 1970, it was disbanded in 2001 and remained defunct until its reconstitution in 2015. It lasted for ten seasons before a second dissolution in 2025, and all members in both incarnations belonged to the Wisconsin Interscholastic Athletic Association.
Starting on October 16, 1963, the Ad Hoc Committee to End Discrimination organized pickets and sit-ins at the Mel's Drive-In locations in San Francisco, Oakland, and Berkeley over the fact that while the restaurant would serve food to African Americans and hired them as cooks, they were not allowed to work "up front" where they could be seen by white customers. More than 100 protesters were arrested. The picketing ended when Harold Dobbs, Mel's Drive-In co-founder who was serving as a San Francisco City supervisor at the time, settled with the protesters and began to allow black workers upfront.
CA7 is a small-molecule oxytocin receptor agonist. It is said to be potent as an agonist of the oxytocin receptor and to show considerable selectivity over the vasopressin V1A receptor, where it displayed no functional activity. However, the exact affinity and activity values at these receptors do not appear to have been disclosed. The chemical synthesis of CA7 has been described. Along with its close analogue WJ0679, CA7 has the smallest chemical structure known for an oxytocin receptor agonist, with WJ0679 having about 60% of the molecular weight of LIT-001 and both WJ0679 and CA7 lacking LIT-001's tail component. Many analogues of WJ0679 and CA7 have been described. CA7 was first described in the scientific literature by a group including Michael Kassiou, Michael Bowen, Iain McGregor, and others at the University of Sydney in 2018. This group has founded a startup pharmaceutical company called Kinoxis Therapeutics and is developing small-molecule oxytocin-related drugs like KNX-100 and the KNX-200 series for potential medical use as of the 2020s.
Sources: en.wikipedia.org
==== Follicular cells ==== The core of a follicle is surrounded by a single layer of follicular cells. When stimulated by thyroid stimulating hormone (TSH), these secrete the thyroid hormones T3 and T4. They do this by transporting and metabolising the thyroglobulin contained in the colloid. Follicular cells vary in shape from flat to cuboid to columnar, depending on how active they are.
A chart or table of nuclides maps the nuclear, or radioactive, behavior of nuclides, as it distinguishes the isotopes of an element. It contrasts with a periodic table, which only maps their chemical behavior, since isotopes (nuclides that are variants of the same element) do not differ chemically to any significant degree, with the exception of hydrogen. Nuclide charts organize nuclides along the X axis by their numbers of neutrons and along the Y axis by their numbers of protons, out to the limits of the neutron and proton drip lines. This representation was first published by Kurt Guggenheimer in 1934 and expanded by Giorgio Fea in 1935, Emilio Segrè in 1945 or Glenn Seaborg. In 1958, Walter Seelmann-Eggebert and Gerda Pfennig published the first edition of the Karlsruhe Nuclide Chart. Its 7th edition was made available in 2006. Today, there are several nuclide charts, four of which have a wide distribution: the Karlsruhe Nuclide Chart, the Strasbourg Universal Nuclide Chart, the Chart of the Nuclides from the Japan Atomic Energy Agency (JAEA), and the Nuclide Chart from Knolls Atomic Power Laboratory in the United States. It has become a basic tool of the nuclear community.
== Life and work == Magati was born in Scandiano, Reggio Emilia, in the landed family of Giorgio and Laura Mattacoda. A brother, Giovanni Battista, became a physician while a sister became the grandmother of Antonio Vallisneri. He studied at Pauda and from 1596, medicine at the University of Bologna. Graduating in 1597 he worked at the Hospital of Santa Maria della Consolazione in Rome. He was influenced by the teachings of Flaminio Rota, Giulio Cesare Claudini, and Giovanni Battista Cortese. He then took the exam of the College of Physicians and became a surgeon at the Hospital of Santa Anna. He then returned to Scandiano and around 1612, through the influence of Marquis Enzio Bentivoglio, he became a lecturer in surgery at Ferrara. In 1618 he became very ill and gave up teaching. He joined the Capuchin order as a lay brother in 1618 and took his vows in Ravenna the next year, and going by the name of Padre Liberato da Scandiano. He continued to practice medicine for the House of Este. In 1647 Magati was operated on for gall-stones at Bologna but he died three days after the surgery. Magati's major contribution was in wound hygiene and healing. He went against the contemporary practice of frequent change in dressing and the use of ointments. He instead suggested that natural processed played a key role in healing and that these processes needed to be aided. For this he is remembered as a fundamental reformer of surgery.
=== 2010 and beyond === By around 2010, Hanmi's R&D had two areas of interest: developing longer-lasting peptide and protein therapeutics using its "Lapscovery" technology, and developing small molecule tyrosine-kinase inhibitors for cancer and autoimmune diseases. Its strategy was to developmental incremental modifications of existing drugs, create new combination drugs, and to develop novel drugs. In August 2014 Hanmi exclusively licensed rights in China for poziotinib, a small molecule EGFR inhibitor, to the Chinese company Luye Pharma; in February 2015 Hanmi licensed rights in the rest of the world outside of South Korea to Spectrum Pharmaceuticals. In March 2015 Hanmi and Lilly signed an exclusive license outside of Asia for Hanmi's small molecule Bruton's tyrosine kinase inhibitor in the field of autoimmune diseases; Lilly paid $50 million upfront and the deal included up to $640 million in milestones and royalties greater than 10%. In November 2015 Hanmi signed three agreements:
Sources: en.wikipedia.org
Water promotes hydrolysis and deamidation, so removing it slows degradation during transport and storage. The dry solid is also less prone to microbial growth than a solution. Reconstitution is therefore performed close to the point of use.
Reversed-phase high-performance liquid chromatography is the standard method for purity and related substances. It separates the main peak from deletion sequences and oxidation products. Mass spectrometry is frequently used alongside it to confirm molecular identity.
Aggregates, truncated sequences, and oxidation products receive the most attention. Size-exclusion chromatography covers aggregates, while reversed-phase methods resolve many chemical variants. Limits are set according to the route of administration and the expected exposure.
It activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. This dual activity separates it from agents that act on only one of the two receptors. The relative contribution of each receptor to clinical effects remains an open area of study.